Division of System Therapeutics and Critical Care Medicine, Geisinger Medical Center, 100 North Academy Avenue, Danville, PA 17822, USA.
Crit Care Clin. 2010 Oct;26(4):679-88. doi: 10.1016/j.ccc.2010.07.003.
Despite the growing epidemic of obesity in the United States, dosing medications in such patients remains poorly studied and understood. Most recommendations are based on small independent studies, case reports, and expert opinion. Applying manufacturer kinetics and dosing recommendations in the obese patient may result in toxicity or treatment failure, leading to increased morbidity, mortality, and hospital length of stay.
尽管美国的肥胖症患者人数不断增加,但针对这些患者的药物剂量问题仍研究不足,了解不够。大多数建议都是基于小型独立研究、病例报告和专家意见。在肥胖患者中应用制造商的药代动力学和剂量建议可能会导致毒性或治疗失败,从而导致发病率、死亡率和住院时间延长。